ACADIA Pharmaceuticals Inc. vs Standard Lithium Ltd — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.52 (market cap $5.07B), while Standard Lithium Ltd trades at $2.41 (market cap $604.50M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 8.4× Standard Lithium Ltd's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| ACAD | SLI | |
|---|---|---|
Market Cap | $5.07B | $604.50M |
Sector | Health | Basic Materials |
52-Week High | $29.41 | $5.65 |
52-Week Low | $20.06 | $1.93 |
Enterprise Value | $4.19B | $467.42M |
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →